Flag of the European Union EU Clinical Trials Register Help

Clinical trials for decitabine OR 2

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44337   clinical trials with a EudraCT protocol, of which   7367   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    38,617 result(s) found for: decitabine OR 2. Displaying page 1,515 of 1,931.
    «« First « Previous 1511  1512  1513  1514  1515  1516  1517  1518  1519  Next» Last»»
    EudraCT Number: 2013-001999-38 Sponsor Protocol Number: TNF-K-006 Start Date*: 2013-10-07
    Sponsor Name:Neovacs SA
    Full Title: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy of Neovacs’ TNF-Kinoid in Adult Subjects with Active Rheumatoid Arthritis despite Methotrexate Therapy
    Medical condition: Active Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    16.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Prematurely Ended) CZ (Prematurely Ended) PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-001645-12 Sponsor Protocol Number: ALPHA2PREVENT Start Date*: 2021-06-28
    Sponsor Name:Oslo University Hospital
    Full Title: Alpha 2 adrenergic receptor agonists for the prevention of delirium and cognitive decline after open heart surgery (ALPHA2PREVENT): randomised controlled trial.
    Medical condition: Postoperative delirium and cognitive decline in male and female participants aged 70+ scheduled for open heart surgery
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003151-34 Sponsor Protocol Number: ET17-093 Start Date*: 2019-01-15
    Sponsor Name:Centre Léon Bérard
    Full Title: A multicenter, randomised, open-label Phase II study to evaluate the clinical benefit of a post-operative treatment associating radiotherapy + Nivolumab + Ipilimumab versus radiotherapy + Capecitab...
    Medical condition: Triple negative breast cancer patients with residual disease after neoadjuvant chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10006292 Breast neoplasms unspecified malignancy HLT
    Population Age: Adults Gender: Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001015-23 Sponsor Protocol Number: APHP180668 Start Date*: 2020-05-13
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Double blind, multicentric, randomized, placebo-controlled trial, evaluating the efficacy of 24-month of bezafibrate in primary sclerosing cholangitis with persistent cholestasis despite ursodeoxyc...
    Medical condition: Adult patients with primary sclerosing cholangitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-001576-30 Sponsor Protocol Number: 15783408 Start Date*: 2016-11-07
    Sponsor Name:CHU TOULOUSE
    Full Title: Interest of Intra-nodal injection of gentamicin for the treatment of suppurated cat scratch disease’s lymphadenitis: a randomized controlled study. "BIGG" : Bartonellosis and intra-nodal injection...
    Medical condition: Bartonellosis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10004145 Bartonellosis PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-002508-42 Sponsor Protocol Number: SBMASTER Start Date*: 2019-12-19
    Sponsor Name:Aarhus University Hospital
    Full Title: A randomized, multicenter, double-blind, placebo-controlled comparison of standard (neo)adjuvant therapy plus placebo versus standard (neo)adjuvant therapy plus atorvastatin in patients with early ...
    Medical condition: Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10006192 Breast cancer NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-003621-10 Sponsor Protocol Number: IC2011.05 Start Date*: 2012-01-19
    Sponsor Name:INSTITUT CURIE
    Full Title: CONSERVATIVE TREATMENT OF PATIENTS WITH RETINOBLASTOMA
    Medical condition: RETINOBLASTOMA
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10038918 Retinoblastoma NOS LLT
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004987-24 Sponsor Protocol Number: APHP180612 Start Date*: 2021-02-18
    Sponsor Name:Assistance Publique-Hopitaux de Paris
    Full Title: Baricitinib in patients with relapsing or naïve dermatomyositis
    Medical condition: Baricitinib in patients with relapsing or naïve dermatomyositis.Multicenter trial, double blind randomized controlled trial with 2 parallel groups. This is an add-on trial with intention to treat a...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10001403 Adult dermatomyositis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-003092-18 Sponsor Protocol Number: 69HCL19_0588 Start Date*: 2019-11-18
    Sponsor Name:Hospices Civils de Lyon
    Full Title: Pilot and Phase 2 Study of the Efficacy of a Treatment Protocol With Dexamethasone Implant Loading Dose in Patients With Diabetic Macular Edema (LOADEX)
    Medical condition: Oedème maculaire diabétique
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10057915 Diabetic macular oedema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000599-38 Sponsor Protocol Number: RC20_0007 Start Date*: 2020-11-26
    Sponsor Name:NANTES CHU
    Full Title: A phase I/II study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of FR104, a novel antagonist pegylated anti-CD28 Fab’ antibody fragment in de novo renal trans...
    Medical condition: Kidney transplant
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004863 10051366 Kidney graft dysfunction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-003795-40 Sponsor Protocol Number: GEMCAD-1802 Start Date*: 2020-12-01
    Sponsor Name:Grupo Español Multidisciplinar en Cáncer Digestivo (GEMCAD)
    Full Title: Randomized and multicentre Phase II study of FOLFOX6m + monoclonal Ab (anti-EGFR or bevacizumab) alone or in combination with hepatic chemoembolization (Lifepearls-Irinotecan) in patients with colo...
    Medical condition: Colorectal cancer patients with metastatic disease limited to the liver with poor prognostic criteria.
    Disease: Version SOC Term Classification Code Term Level
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000605-24 Sponsor Protocol Number: ESPERANZA_COVID Start Date*: 2021-07-08
    Sponsor Name:IDIAP Jordi Gol
    Full Title: Double-blind Randomized Clinical Trial, Placebo-controlled to Assess the Efficacy of Montelukast in Mild-moderate Respiratory Symptoms in Patients With Long-COVID: E-SPERANZA COVID PROJECT
    Medical condition: Patients with a history of SAR-Cov-2 infection (PCR positive) with long Covid-19 and mild or moderate respiratory symptoms of more than 1 month and less than 4 months of evolution, attended in Prim...
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-001316-26 Sponsor Protocol Number: APHP200007 Start Date*: 2022-09-12
    Sponsor Name:Assistance Publique Hôpitaux de Paris / DRCI
    Full Title: Multicenter, randomized, prospective trial comparing the Efficacy and Safety of Adalimumab to that of Tocilizumab in severe uveitis of Behçet’s disease UVB Study
    Medical condition: severe uveitis of Behçet’s disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10071139 Behcet's uveitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003447-25 Sponsor Protocol Number: CHUBX2021/08 Start Date*: 2021-12-01
    Sponsor Name:CHU DE BORDEAUX
    Full Title: Strategic treatment Pause of first-line Immune Check point Inhibitor + VEGFR-Tyrosine Kinase Inhibitor in good or intermediate risk with only one adverse prognostic factor in metastatic renal cell ...
    Medical condition: Metastatic renal cell carcinoma (mRCC) with a good or only one adverse prognostic factor intermediate risk per IMDC score
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-002996-36 Sponsor Protocol Number: 15TETE04 Start Date*: 2021-06-23
    Sponsor Name:INSTITUT CLAUDIUS REGAUD
    Full Title: A Phase I Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTA0-Tyr3-Octreotate in Children with Refractory or Recurrent Neuroblastoma expressing som...
    Medical condition: Recurrent or refractory neuroblastoma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029260 Neuroblastoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066595 Neuroblastoma recurrent PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003753-13 Sponsor Protocol Number: P160909 Start Date*: 2019-03-19
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
    Full Title: Multicentre, randomized, prospective trial comparing the efficacy and safety of Infliximab to tocilizumab in refractory or relapsing Takayasu arteritis
    Medical condition: Patients with refractory or relapsing Takayasu Arteritis desease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004490-27 Sponsor Protocol Number: 18POUM06 Start Date*: 2019-09-11
    Sponsor Name:INSTITUT CLAUDIUS REGAUD
    Full Title: A multicentric Phase II, open-label study evaluating the efficacy of the combination of hypofractionated stereotactic radiation therapy with the anti-PDL1 immune checkpoint inhibitor Durvalumab in ...
    Medical condition: Non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002852-34 Sponsor Protocol Number: S61508 Start Date*: 2020-02-10
    Sponsor Name:UZLeuven
    Full Title: Progression-free Survival after Minimally Invasive Surgical Microwave Ablation plus Durvalumab (MEDI4736) and Tremelimumab for Unresectable Non-metastatic Locally Advanced Pancreatic Cancer. MIMIPA...
    Medical condition: Unresectable Locally Advanced Non Metastatic Pancreatic Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10033606 Pancreatic cancer non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-004935-22 Sponsor Protocol Number: TA-8995-303 Start Date*: 2020-10-01
    Sponsor Name:NewAmsterdam Pharma BV
    Full Title: A Placebo-Controlled, Double-Blind, Randomized Phase 2 Study to Evaluate the Effect of Obicetrapib in Combination with Ezetimibe in Participants with Mild Dyslipidemia
    Medical condition: mild dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004848 10020049 High cholesterol LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2022-002924-11 Sponsor Protocol Number: LOLAbiome Start Date*: 2023-01-09
    Sponsor Name:CBmed GmbH
    Full Title: An observational study on the effect of L-ornithine-L-aspertate (LOLA) on the Flavonifractor abundance in the gut microbiome in liver cirrhosis
    Medical condition: Liver cirrhosis with covert or overt hepatic encephalopathy (grade 0-2)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10024667 Liver cirrhosis LLT
    20.0 100000004852 10014630 Encephalopathy hepatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 1511  1512  1513  1514  1515  1516  1517  1518  1519  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 22 08:10:02 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA